NMPA Approves Rapid Medical Ltd’s Intracranial Thrombectomy Stent for Marketing
The National Medical Products Administration (NMPA) has granted marketing approval to Rapid Medical Ltd for...
Luye Pharma Launches Rykindo in US, a First for Chinese CNS Drug
China-based Luye Pharma Group (HKG: 2186) has announced the official commercial operation of its Rykindo...
CytoMed Therapeutics Partners with CNK Therapeutics for CAR Gene Grafting Technology
Singapore-based cell therapy developer CytoMed Therapeutics Ltd (NASDAQ: GDTC) has announced the signing of a...
CSPC Pharmaceutical Group Receives FDA Approval for NBL-028 Bispecific Antibody Clinical Study
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received the green...
Aurisco Pharmaceutical Passes US FDA cGMP Inspection at Jiangsu Plant
China-based Aurisco Pharmaceutical (SHA: 605116) has announced the successful completion of a current Good Manufacturing...
Formosa Pharmaceuticals and Eyenovia Inc. Sign Licensing Deal for Ocular Surgery Treatment
Taiwan’s Formosa Pharmaceuticals (TPE: 6838) and US-based Eyenovia Inc., (NASDAQ: EYEN) have signed their second...
Biocytogen Pharmaceuticals Opens US Subsidiary Biocytogen Boston Corp. in Massachusetts
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315) has announced the official start of operations...
CanSino Biologics Receives Halal Certificate for COVID-19 Vaccine in Indonesia
China-based CanSino Biologics (SHA: 688185, HKG: 6185) has announced that it has received a halal...
Innovent Biologics’ Tafolecimab Receives NMPA Approval for Hypercholesterolemia Treatment
China-based Innovent Biologics Inc. (HKG: 1801) has announced that it has received market approval from...
European Commission Approves AbbVie’s Aquipta for Migraine Prevention in Adults
The European Commission (EC) has granted marketing approval to AbbVie (NYSE: ABBV) for its drug...
BMS Announces Positive Phase I/II Results for Repotrectinib in ROS1-Positive NSCLC
Bristol-Myers Squibb (BMS, NYSE: BMY) has released new data from a Phase I/II trial featuring...
Immunofoco’s IMC008 Earns Orphan Drug Designation for Gastric Cancer from FDA
Suzhou-based cell therapy developer Immunofoco has announced that it has received orphan drug designation (ODD)...
Seagen’s Tukysa Meets Primary Endpoint in Phase III Study for HER2+ Breast Cancer
Seagen (NASDAQ: SGEN), currently in the process of being acquired by Pfizer (NYSE: PFE), has...
Medtronic’s Kanghui Partners with Huashan Hospital to Create Neuroscience Innovation Platform
US major Medtronic, Inc.’s (NYSE: MDT) unit, Kanghui, has entered into a partnership with Huashan...
JD Healthcare Reports 34% Revenue Growth and Triples Non-IFRS Profits in 2023 Interim Report
JD Healthcare, a subsidiary of China’s e-commerce giant JD.com (NASDAQ: JD), has released its 2023...
Eisai’s Shanghai Unit Faces RMB 900,000 Penalty for Violating Drug Administration Law
Eisai Co., Ltd’s (TYO: 4523) Shanghai unit has been hit with an administrative penalty of...
Inmagene Biopharmaceuticals Initiates Global Study for IMG-007 in Atopic Dermatitis
China-based Inmagene Biopharmaceuticals has announced the first patient dosing in a global, multi-center, proof-of-concept study...
Sinovac Biotech Reports H1 2023 Financials with Significant Sales Decline from COVID-19 Boom
Sinovac Biotech Ltd (NASDAQ: SVA) has published its financial results for the first half of...
Gracell Biotechnologies Reports Q2 2023 Financials, Highlights GC012F in Melanoma Treatment
Suzhou-based biotech company Gracell Biotechnologies Inc., (NASDAQ: GRCL) has reported its financial results for the...